肿瘤免疫治疗中,程序性死亡受体1(PD-1)及程序性死亡受体配体1(PD-L1)的研究为晚期肺癌的综合治疗提供了新的途径.肺癌免疫治疗中约有20％的非小细胞肺癌患者能从中获益,而PD-L1高表达的肺癌患者生存获益更多.目前国内外有关PD-1表达的相关研究还较少,对于PD-1/PD-L1表达含量的检测也多集中在肿瘤组织.随着液体活组织检查技术的研究进展,外周血检测的便捷性和准确性也日趋受到重视,但对于肿瘤免疫治疗疗效预测的生物学指标还较少,检测的统一标准及准确性还需要更多的临床实践及探索.文章就PD-1与PD-L1在肺癌患者组织及外周血中表达的研究情况进行综述,旨在为肺癌免疫检查点阻断剂的治疗提供参考.%In tumor immunotherapy, the study of programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1) provides a new approach for the comprehensive treatment of advanced lung cancer. About 20％ of patients with non-small cell lung cancer could benefit from lung cancer immunotherapy, while those with high PD-L1 expression will benefit more. At present, there are few related studies on PD-1 expression at home and abroad, and the detection of PD-1/PD-L1 expressions is mostly concentrated in tumor tissues. With the research progress of liquid biopsy technology, the convenience and accuracy of peripheral blood testing are also receiving more and more attention. However, there are still few biological indicators for predicting the efficacy of tumor immunotherapy, and the uniform standard and accuracy of testing still need more clinical practice and exploration. This article reviews the research on the expressions of PD-1 and PD-L1 in tissues and peripheral blood of patients with lung cancer, aiming to provide reference for the treatment of lung cancer with immune checkpoint blockers.
展开▼
